Swedish Orphan Biovitrum AB (publ) (Sobi) announces its results for the third quarter 2021. Total revenue amounted to SEK 3,761 M, a 29 per cent growth at CER compared with the same period 2020. EBITA was SEK 1,166 M, resulting in an EBITA margin of 31 per cent.

July - September

Total revenue SEK 3,761 M (2,970), +27 per cent, +29 per cent at constant exchange rates (CER)

Haematology revenue SEK 2,291 M (2,147), +9 per cent at CER of which Elocta SEK 1,035 M (1,115), -6 per cent at CER, Alprolix SEK 430 M (435), unchanged at CER, and Doptelet SEK 400 M (145), +187 per cent at CER

Immunology revenue SEK 1,144 M (619), +89 per cent at CER of which Kineret SEK 516 M (463), +13 per cent at CER, Synagis SEK 374 M (46), +769 per cent at CER, and Gamifant SEK 255 M (110), +139 per cent at CER

EBITA1 SEK 1,166 M (933), EBITA margin1 31 per cent (31)

Earnings per share (EPS) before dilution SEK 1.60 (0.94)

Cash flow from operating activities SEK 257 M (381)

January - September

Total revenue SEK 10,633 M (10,680), unchanged and +7 per cent at CER

Haematology revenue SEK 6,294 M (6,578), +1 per cent at CER of which Elocta SEK 2,896 M (3,514), -14 per cent at CER, Alprolix SEK 1,281 M (1,286), +4 per cent at CER, and Doptelet SEK 810 M (396), +126 per cent at CER

Immunology revenue SEK 3,450 M (3,133), +21 per cent at CER, of which Kineret SEK 1,608 M (1,493), +16 per cent at CER, Synagis SEK 1,286 M (1,294), +13 per cent at CER, and Gamifant SEK 556 M (346), +78 per cent at CER

EBITA1 SEK 3,572 M (4,124), EBITA margin1 34 per cent (39)

EPS before dilution SEK 4.87 (5.92)

Cash flow from operating activities SEK 3,349 M (4,209)

Significant events after the reporting period

Aspaveli (pegcetacoplan) for PNH: positive CHMP opinion in the EU

Financial outlook 2021 - refined

Revenue for the full year 2021 is expected to be in the range of SEK 14,500-15,000 M

EBITA margin is expected to be in the range of 33-35 per cent of revenue

Guido Oelkers, CEO and President:

'We saw continued growth and pipeline progress in the third quarter of 2021, and it is satisfying to see that results are confirming our strategic direction. Overall, our two main business areas are in solid shape and they progressed as expected.'

Contact:

Thomas Kudsk Larsen

Head of Communication and Investor Relations

Maria Kruse

Director of Communication and Investor Relations

Sobi

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology, and specialty indications. Sobi employs approximately 1,500 people across Europe, North America, the Middle East, Russia, and Asia. In 2020, Sobi's revenues amounted to SEK 15.3 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.

Contact:

Swedish Orphan Biovitrum AB (publ)

Postal address SE-112 76 Stockholm

Sweden

Phone: 46 8 697 20 00

WEB: www.sobi.com

(C) 2021 Electronic News Publishing, source ENP Newswire